#Nasdaq #Biotech It ought to correct overbought

INDEX:NBI   Nasdaq Biotechnology Index
It ought to correct overbought Nasdaq Biotechnology Index:
The Nasdaq Biotech index             has grown about 50 percent since Yellen's valuation comments. Superarando por mucho el desempeño de los indices composite y S&P500             , this boom is due primarily to the pharmaceutical companies who have monopolized the attention of investors the past few months, beyond the debate of whether exist a bubble formation the Nasdaq Biotechnology Index             It ought to correct their overbought at least 6% as it has done in later months

Biotechs could be the early warning for stocks

The uncertainty caused by the excessive increase in the valuation of shares, based on the promises of extraordinary cash flows through products that are still in experimental stages of research and development is an increasingly risky. The appetite for higher-yielding assets and high risk is associated with the availability of liquidity injected by central banks in the market at low interest rates, when a change occurs in this scenario the liquidation of long positions will result in a significant correction that all expect.
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out